SmPC: The EU Label and How It Differs From US Labelling

The Summary of Product Characteristics is the approved product information for a medicine in the European Union. It is the legal basis on which the product is marketed, and it is written for healthcare professionals.

It is approved as part of the marketing authorisation, which is the key difference from a US-style label: in the EU the label text is the authorisation.

The structure is fixed

The SmPC follows a prescribed section order, and the numbering is stable enough that people cite it directly:

• 1 Name of the medicinal product
• 2 Qualitative and quantitative composition
• 3 Pharmaceutical form
• 4 Clinical particulars, containing therapeutic indications (4.1), posology and administration (4.2), contraindications (4.3), special warnings (4.4), interactions (4.5), fertility, pregnancy and lactation (4.6), effects on driving (4.7), undesirable effects (4.8), overdose (4.9)
• 5 Pharmacological properties
• 6 Pharmaceutical particulars, including shelf life and storage
• 7 Marketing authorisation holder
• 8 to 10 Authorisation number and dates

Section 4.8 and section 4.4 are where most safety-driven changes land.

The related documents

Package Leaflet (PIL). The patient-facing document, derived from the SmPC and required to be consistent with it. It must also pass user testing for readability, which is an EU-specific requirement with no US equivalent.

Labelling, meaning the text on the carton and immediate packaging.

Together these are the product information, and a change to the SmPC generally cascades into the PIL and often the packaging.

How it differs from US prescribing information

Approved text versus content requirement. The SmPC is approved as part of the authorisation. US prescribing information follows the Physician Labeling Rule format, and changes run through the supplement system.

Structure. The SmPC's numbered sections and the PLR's Highlights and Full Prescribing Information are different documents solving the same problem differently.

Patient information. The EU PIL is mandatory and user-tested. US patient labelling requirements vary by product.

Both derive from the same company core data sheet, which is what keeps them saying the same thing.

Changing one

An SmPC change is a variation, and the type determines the timeline. A safety-driven change to section 4.4 or 4.8 is usually a Type II variation with an assessment period; an administrative change may be Type IA and notifiable.

For a centrally authorised product the variation goes through EMA. For nationally authorised products it goes through each member state, or through the mutual recognition and decentralised procedures, which is why one safety change becomes many national procedures.